From: Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma
Variables | Full cohort (n = 51) | R-CHOP cohort (n = 43) | ||
---|---|---|---|---|
Mean ± SD | p value | Mean ± SD | p value | |
Age, years | Â | 0.415 | Â | 0.357 |
 < 60 | 18.2 ± 32.6 |  | 7.8 ± 12.0 |  |
 ≥ 60 | 12.0 ± 13.7 |  | 11.6 ± 13.4 |  |
Sex | Â | 0.603 | Â | 0.353 |
 Male | 16.0 ± 27.7 |  | 8.5 ± 10.4 |  |
 Female | 12.5 ± 15.4 |  | 12.2 ± 15.4 |  |
Primary site | Â | 0.504 | Â | 0.595 |
 Nodal | 11.5 ± 15.3 |  | 8.6 ± 14.3 |  |
 Extranodal | 16.2 ± 26.8 |  | 10.8 ± 12.3 |  |
Ann Arbor stage | Â | 0.379 | Â | 0.731 |
 I, II | 17.3 ± 29.2 |  | 10.7 ± 12.8 |  |
 III, IV | 11.5 ± 14.1 |  | 9.4 ± 13.2 |  |
IPI groupa | Â | 0.664 | Â | 0.985 |
 Low (0–2) | 11.2 ± 13.0 |  | 10.1 ± 12.3 |  |
 High (3–5) | 13.0 ± 15.6 |  | 10.1 ± 14.1 |  |
B symptomsa | Â | 0.737 | Â | Â |
 Absent | 15.7 ± 27.4 |  | 10.4 ± 12.2 |  |
 Present | 13.4 ± 15.6 |  | 9.5 ± 14.4 |  |
ECOG PSa | Â | 0.886 | Â | 0.310 |
 0, 1 | 12.0 ± 13.8 |  | 10.9 ± 13.5 |  |
 ≥ 2 | 12.8 ± 16.0 |  | 5.1 ± 5.9 |  |
LDHa | Â | 0.466 | Â | 0.785 |
 Normal | 10.2 ± 13.2 |  | 9.5 ± 12.6 |  |
 Elevated | 13.2 ± 14.6 |  | 10.6 ± 13.3 |  |
BM involvementa | Â | 0.561 | Â | 0.452 |
 Absent | 11.0 ± 12.5 |  | 9.1 ± 11.2 |  |
 Present | 19.2 ± 24.8 |  | 24.1 ± 27.9 |  |
Number of extranodal sitesa | Â | 0.182 | Â | 0.582 |
 0, 1 | 12.9 ± 15.0 |  | 10.7 ± 14.0 |  |
 ≥ 2 | 8.1 ± 8.0 |  | 8.1 ± 8.0 |  |
EBER | Â | 0.820 | Â | 0.804 |
 Negative | 14.1 ± 24.4 |  | 9.9 ± 11.2 |  |
 Positive | 16.0 ± 19.8 |  | 11.2 ± 20.4 |  |
Hans classification | Â | 0.253 | Â | 0.833 |
 GCB | 20.7 ± 38.0 |  | 9.4 ± 11.5 |  |
 Non-GCB | 12.2 ± 14.6 |  | 10.4 ± 13.5 |  |